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ABSTRACT
The National Comprehensive Cancer Network (NCCN)-International Prognostic 
Index (IPI) and GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de 
Médula Ósea)-IPI were developed to enable better risk prediction of patients with 
diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness 
of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL 
particularly in terms of determining high-risk patients. Among 439 patients who were 
enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, 
risk groups were classified according to the three IPIs and the prognostic significance 
of individual IPI factors and IPI models were analyzed and compared. All three IPI 
effectively separated the analyzed patients into four risk groups according to overall 
survival (OS). Estimated 5-year OS of patients classified as high-risk according to the 
IPI was 45.7%, suggesting that the IPI is limited in the selection of patients who are 
expected to have a poor outcome. In contrast, the 5-year OS of patients stratified as 
high-risk according to NCCN- and GELTAMO-IPI was 31.4% and 21.9%, respectively. 
The results indicate that NCCN- and GELTAMO-IPI are better than the IPI in predicting 
patients with poor prognosis, suggesting the superiority of enhanced, next-generation 
IPIs for DLBCL.
INTRODUCTION
The International Prognostic Index (IPI) has been 
widely adapted in clinical practice since its introduction 
almost 25 years ago for patients with aggressive non-
Hodgkin lymphoma (NHL) [1]. The IPI is clinically useful 
because it is reproducible, allows convenient scoring and 
categorizes patients. Several modified versions of IPI 
according to the subtypes of NHL have been described [2–
4]. The modifications and the original IPI that comprises 
five factors, has been used in patients with aggressive 
NHL, including DLBCL [1]. The addition of rituximab 
to chemotherapy has improved the outcome of patients 
with DLBCL, and necessitated a re-evaluation of the 
role of the IPI. It was concluded that the IPI remains a 
valid prognostic indicator for patients with DLBCL in the 
rituximab era [5].
Despite maintaining its overall prognostic value, 
criticisms of the IPI are that it cannot effectively separate 
patients who are expected to have a poor outcome in the 
rituximab era [6]: contrast to pre-rituximab era, 5-year 
overall survival (OS) of the IPI-defined high-risk group 
was significantly improved, approaching 40 to 50% 
[7–10], suggesting that even patients classified into the 
poorest risk group according to the IPI have up to a 50% 
chance of cure. Sehn et al. reported a convergence of 
Kaplan-Meier curves among high-intermediate (HI) and 
high-risk categories defined by the IPI, and suggested a 
Revised-IPI (R-IPI) for better prediction of survival [7]. 
However, in the R-IPI, the 4-year OS of patients with 
high-risk category was 55%, and patients expected to have 
dismal prognosis were not distinguished [7].
In 2014, Zhou et al. proposed the National 
Comprehensive Cancer Network (NCCN)-IPI [8], which 
applied enhanced stratifications and scoring of age and 
serum lactate dehydrogenase (LDH) ratio to the upper 
limit of normal (ULN). In addition, they included the 
involvement of major extranodal organs [bone marrow, 
central nervous system (CNS), liver/gastrointestinal 
tract, and lung] as a factor of the NCCN-IPI instead of 
conventional definition of “involvement of >1 extranodal 
sites” according to the IPI. In their study using the NCCN 
study cohort comprising 1,650 individuals from seven 
NCCN centers, and the British Columbia Cancer Agency 
(BCCA) validation cohort (n = 1,138), the 5-year OS of 
NCCN-IPI-defined high-risk patients was 33% in the 
NCCN cohort and 38% in the BCCA cohort, suggesting the 
improved selection of high-risk group compared to the IPI 
[8]. Recently, the Grupo Español de Linfomas/Trasplante 
Autólogo de Médula Ósea (GELTAMO)-IPI Project 
Investigators proposed a new IPI incorporating the elevation 
of beta-2 microglobulin (B2MG) above ULN and enhanced 
scoring system but different from NCCN-IPI (Table 1). 
They reported that the GELTAMO-IPI yielded a better 
discrimination of high-risk DLBCL patients compared to 
the NCCN-IPI (5-year OS 39% vs. 49%) [9].
The purpose of the present study was to validate 
and compare the effectiveness of the risk assessment 
between IPI, NCCN-IPI, and GELTAMO-IPI among 
patients with DLBCL treated with rituximab-CHOP 
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(R-CHOP) immunochemotherapy, particularly in terms of 
determining high-risk patients.
RESULTS
Patient characteristics and classification
Among 603 patients who enrolled in the PROCESS 
study, 164 patients were excluded [8 patients did not 
satisfy inclusion criteria and 156 patients lacked data 
of baseline serum beta-2-microglobulin (B2MG)] and 
the remaining 439 patients who had complete clinical, 
radiologic, and laboratory data enabling their classification 
according to the three IPI schemes were included in the 
current study (Figure 1).
The baseline characteristics of the analyzed 
patients were summarized in Table 2. Overall 
characteristics of the 439 patients did not deviate from 
those of all the patients from the PROCESS cohort. 
During the median follow-up duration of 55.0 months 
(95% CI 53.1 - 57.0), 133 patients (30.3%) underwent 
progression-free survival (PFS) events and 120 patients 
(27.3%) died. Five-year PFS and OS rates were 66.8% 
and 70.6%, respectively.
According to the IPI, the proportion of low-risk 
group was the highest (43%). In the NCCN-IPI, the 
number of low-intermediate (LI)-risk group was the 
highest (45%). In the GELTAMO-IPI, most patients were 
classified into LI-risk group (61%). Patterns of Distributio 
of patients according to the three IPI were overall 
similar with those of original NCCN and GELTAMO 
studies (Figure 2) [8, 9]. The NCCN- and GELTAMO-
IPI classified a relatively smaller proportion of patients 
into the high-risk group (8.9% in NCCN-IPI and 6.8% in 
GELTAMO-IPI, respectively), compared to the IPI (18.2% 
in the high-risk group).
Table 1: Comparison of factors and scoring of IPI, NCCN-IPI, and GELTAMO-IPI
IPI Score NCCN-IPI Score GELTAMO-IPI Score
Age (years) ≤ 60 0 ≤ 40 0 < 65 0
> 60 1 41-60 1 65-79 1
61-75 2 ≥ 80 2
> 75 3
Ann Arbor stage I-II 0 I-II 0 I-II 0
III-IV 1 III-IV 1 III-IV 1
B2MG, normalized ratio Not included Not included ≤ 1 0
> 1 1
ECOG performance status 0-1 0 0-1 0 0-1 0
≥ 2 1 ≥ 2 1 2 1
3-4 2
Extranodal sites 0-1 0 No distinct sites* 0 Not included
≥ 2 1 Any distinct sites* 1
Serum LDH, normalized ratio ≤ 1 0 ≤ 1 0 ≤ 1 0
> 1 1 >1 to ≤ 3 1 > 1 1
> 3 2
Risk scoring low 0-1 low 0-1 low 0
Low-intermediate 2 Low-intermediate 2-3 Low-intermediate 1-3
High-intermediate 3 High-intermediate 4-5 High-intermediate 4
High 4-5 High ≥ 6 High ≥ 5
*Distinct extrnodal sites defined by NCCN-IPI: central nervous system, bone marrow, liver/gastrointestinal tract, or lung 
IPI, International Prognostic Index; NCCN, National Comprehensive Cancer Network; GELTAMO, Grupo Español de 
Linfomas/Trasplante Autólogo de Médula Ósea; B2MG, beta-2 microglobulin; ECOG, Eastern Cooperative Oncology 
Group; LDH, lactate dehydrogenase.
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Prognostic significance of individual IPI factor in 
the IPI, NCCN-IPI, and GELTAMO-IPI
All five factors of the IPI showed a significant 
difference of OS with hazard ratios (HRs) between 2.27 
to 4.10 (Table 3). Enhanced stratification of age (in the 
NCCN- and GELTAMO-IPI), serum LDH (in the NCCN-
IPI), and performance status (PS; in the GELTAMO-IPI) 
resulted in more effective risk stratification, except in 
groups between ≤ 40 vs. 41-60 years of age in the NCCN-
IPI (p = 0.175). Involvement of extranodal sites designated 
by the NCCN-IPI failed to show prognostic significance 
(p = 0.755). Patients with an increased serum B2MG level 
showed significantly inferior OS compared to those with 
not increased B2MG. Ann Arbor staging lost its prognostic 
significance in the multivariate analyses performed in 
all three IPIs. Otherwise, most factors maintained an 
independent prognostic significance (Table 4).
Stratification of patients according to the IPI, 
NCCN-IPI, and GELTAMO-IPI
All three IPI schemes effectively separated the 
analyzed patients into four risk groups according to OS 
(Table 5 and Figure 3). Estimated 5-year OS of patients 
classified as high-risk group according to IPI was 
45.7%, suggesting that the IPI is limited in the selection 
of patients who are expected to have poor outcome. In 
contrast, the 5-year OS of patients stratified as high-risk 
according to NCCN- and GELTAMO-IPI were 31.4%, 
and 21.9%, respectively (Table 5). In the reclassification 
calibration statistic analysis, NCCN- and GELTAMO-IPI 
showed superior risk prediction (separating patients into 
high-risk vs. non-high-risk) compared to the IPI (Table 6). 
Comparison between NCCN- and GELTAMO-IPI was not 
statistically feasible as patient numbers of high-risk group 
by either of two IPIs were small and 23 patients were 
classified into high-risk by both NCCN- and GELTAMO-
IPI.
DISCUSSION
In the present study, the NCCN- and GELTAMO-
IPI, the revised versions of the IPI that feature enhanced 
scoring systems (and the addition of serum B2MG in case 
of GELTAMO-IPI), showed improved prognostic power to 
detect patients with dismal prognosis compared to the IPI.
The population we analyzed reflects a real-world 
clinical practice of DLBCL patients because they were 
accrued from 27 medical centers of a nation-wide 
distribution, and our prospective cohort had no specific 
interventions relevant to patient selection or additional 
investigative therapy. Our patients had a median age of 60 
years (57 years in the NCCN-cohort and 63 years in the 
BCCA-cohort of the NCCN-IPI study and 60 years in the 
GELTAMO-IPI study, respectively). Forty eight percent 
of the patients were > 60 years of age, 57% were males, 
51% were LDH >1x ULN, 50% were Ann Arbor stage 
III or IV, and 12% of the analyzed patients were PS >1, 
showing that these characteristics had not significantly 
deviated from the populations in the original studies of 
the NCCN- and GELTAMO-IPI.
In the present study, involvement of the NCCN-
designated extranodal sites had no prognostic significance. 
The prognostic implication of gastrointestinal tract, one 
of the designated involved sites, is controversial. Studies 
have suggested poor survival [11], no association [10], and 
even favorable outcomes [12]. In a Japanese retrospective 
study of 1,221 patients, the involvement of the small 
intestine was an IPI-independent poor prognostic factor, 
whereas involvement of stomach or colon was not [13]. 
In addition, the involvement of extranodal sites other than 
Figure 1: CONSORT diagram of the current study. 
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Table 2: Patient characteristics
Analyzed patients n = 439
n %
Sex Male 250 57
Median age, years (range) 60 (20 - 89)
Age (by NCCN-IPI) ≤ 40 years 52 12
41- 60 years 176 40
61-75 years 162 37
> 75 years 49 11
Age (by GEMTAMO-IPI) < 65 years 266 61
65-79 years 152 35
≥ 80 years 21 5
Performance status ECOG 0 or 1 385 88
ECOG 2 36 8
ECOG 3 or 4 18 4
Ann Arbor stage III/IV 221 50
Serum LDH Not increased 213 49
> ×1~3 ULN 194 44
> ×3 ULN 32 7
Extranodal sites (any)(No. ≥ 2 involved 158 36
Extranodal sites (by NCCN-IPI) Involved (any) 200 46
Bone marrow 62 14
CNS 10 2
Liver/GI 140 32
Lung 30 7
Serum B2MG Not increased
> ×1 ULN
262
177
60
40
IPI (score) Low (0-1) 190 43
Low-intermediate (2) 87 20
High-intermediate (3) 82 19
High (4-5) 80 18
NCCN-IPI (score) Low (0-1) 71 16
Low-intermediate (2-3) 199 45
High-intermediate (4-5) 130 30
High (≥ 6) 39 9
GELTAMO-IPI (score) Low (0) 91 21
Low-intermediate (1-3) 269 61
High-intermediate (4) 49 11
High (≥5) 30 8
ECOG, Eastern Cooperative Oncology Group; LDH, Lactate dehydrogenase; IPI, International Prognostic Index; NCCN, 
National Comprehensive Cancer Network; B2MG, beta-2 microglobulin; GELTAMO, Grupo Español de Linfomas/
Trasplante Autólogo de Médula Ósea.
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Table 3: Univariate Cox regression analysis for impacts of variables from 3 IPIs on overall survival
Variables IPI NCCN-IPI GELTAMO-IPI
HR (95% CI) p Score HR (95% CI) p Score HR (95% CI) p Score
Age (IPI) < 0.001
 ≤ 60 years 1 0
 > 60 years 3.05 (2.07 - 4.49) 1
Age (NCCN-IPI) < 0.001
 ≤ 40 years 1 0
 41-60 years 1.96 (0.77 - 5.04) (0.160) 1
 61-75 years 4.37 (1.75 - 10.93) (0.002) 2
 > 75 years 9.10 (3.51 - 23.580) (< 0.001) 3
Age (GELTAMO-IPI) < 0.001
 < 65 years 1 0
 65-79 years 3.24 (2.20 - 4.75) (< 0.001) 1
 ≥ 80 years 5.01 (2.64 - 9.49) (< 0.001) 2
LDH (IPI- and GELTAMO-IPI) < 0.001 < 0.001
 Not increased 1 0 1 0
 Increased 2.77 (1.86 - 4.01) 1 2.77 (1.86 - 4.01) 1
LDH (NCCN-IPI) < 0.001
 Not increased 1 0
 > 1~3 upper limit of normal 2.20 (1.45 - 3.33) (< 0.001) 1
 > x3 upper limit of normal 8.80 (5.19 - 14.91) (< 0.001) 2
ECOG PS (IPI and NCCN-IPI) < 0.001 < 0.001
 0-1 1 0 1 0
 ≥ 2 4.28 (2.86 - 6.41) 1 4.28 (2.86 - 6.41) 1
ECOG PS (GELTAMO-IPI) < 0.001
 0-1 1 0
 2 3.16 (1.92 - 5.20) (< 0.001) 1
 3-4 8.43 (4.76 - 14.93) (< 0.001) 2
Ann Arbor staging (common) < 0.001 < 0.001 < 0.001
 I-II 1 0 1 0 1 0
 III-IV 2.32 (1.59 - 3.40) 1 2.32 (1.59 - 3.40) 1 2.32 (1.59 - 3.40) 1
Extranodal lesion (IPI) < 0.001
 0-1 site 1 0
 > 1 sites 2.35 (1.64 - 3.36) 1
Extranodal sites (NCCN-IPI) 0.755
 Not involved 1 0
 Involved 1.10 (0.77 - 1.57) 1
Serum B2MG (GELTAMO-IPI) < 0.001
 Not increased 1 0
 Increased 3.08 (2.13 - 4.47) 1
NCCN, National Comprehensive Cancer Network; GELTAMO, Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea; IPI, International 
Prognostic Index; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; B2MG, beta-2 microglobulin.
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Figure 2: Patient distributions according to risk group in respective three IPIs. 
Table 4: Results of multivariate analysis of IPI factors in respective 3 IPIs on overall survival
Hazard ratio (95% CI) p
IPI
 Age > 60 years 2.75 (1.86 - 4.06) < 0.001
 LDH increased 2.03 (1.34 - 3.06) 0.001
 ECOG PS ≥ 2 2.84 (1.88 - 4.30) < 0.001
 Extranodal lesion > 1 site 1.68 (1.16 - 2.44) 0.006
NCCN-IPI
 Age 41-60 years 1.76 (0.69 - 4.53) 0.239
 Age 61-75 years 3.63 (1.45 - 9.08) 0.006
 Age > 75 years 6.51 (2.48 - 17.15) < 0.001
 LDH > 1~3 upper limit of normal 2.05 (1.34 - 3.13) 0.001
 LDH > ×3 upper limit of normal 5.45 (3.11 - 9.55) < 0.001
 ECOG PS ≥ 2 2.26 (1.45 - 3.53) < 0.001
GELTAMO-IPI
 Age 65-79 years 2.36 (1.57 - 3.53) < 0.001
 Age ≥ 80 years 4.07 (2.04 - 8.14) < 0.001
 LDH increased 2.08 (1.36 - 3.18) 0.001
 ECOG PS 2 2.22 (1.33 - 3.69) 0.002
 ECOG PS 3-4 3.93 (2.16 - 7.17) < 0.001
 Serum B2MG increased 1.55 (1.02 - 2.35) 0.039
IPI, International Prognostic Index; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; NCCN, 
National Comprehensive Cancer Network; GELTAMO, Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea; 
B2MG, beta-2 microglobulin.
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the NCCN-defined lesions has been suggested as a poor 
prognostic indicator, including the genitourinary tract 
[14] and female reproductive organ [10]. In the validation 
of the NCCN-IPI by the GELTAMO group, the NCCN-
designated extranodal disease lost its prognostic value in 
multivariate analysis [9], and therefore it was not included 
in GELTAMO-IPI. A large-scale retrospective analysis (n 
= 25,992) using the Surveillance, Epidemiology, and End 
Results (SEER) database from 2004 to 2009 reported that 
sites of extranodal involvement are more prognostic than 
the number of involved sites [11]. However, a Danish-
Canadian study reported that involvement of three or 
more extranodal sites is independently associated with 
dismal outcomes [10]. Considering the above results, 
the prognostic impact of extranodal sites in terms of its 
number or anatomic location is still an area of debate.
In our study, advanced Ann Arbor staging lost 
its prognostic significance in multivariate analyses 
Table 5: Results of risk stratification according to IPI, NCCN-IPI, and GELTAMO-IPI
  p-value (by log-rank test) Survival
L LI HI H 5-year 
PFS
5-year OS
IPI
  L - 0.002 < 0.001 < 0.001 83.9% 86.6%
  LI 0.002 - 0.100 < 0.001 67.7% 68.1%
  HI < 0.001 0.100 - 0.016 56.9% 58.2%
  H < 0.001 < 0.001 0.016 - 41.1% 45.7%
NCCN-IPI
  L - 0.029 < 0.001 < 0.001 89.9% 91.1%
  LI 0.029 - < 0.001 < 0.001 77.7% 79.8%
  HI < 0.001 < 0.001 - < 0.001 54.6% 56.8%
  H < 0.001 < 0.001 < 0.001 - 26.9% 31.4%
GELTAMO-IPI
  L - < 0.001 < 0.001 < 0.001 90.8% 90.1%
  LI < 0.001 - < 0.001 < 0.001 69.9% 72.6%
  HI < 0.001 < 0.001 - 0.001 47.9% 51.7%
  H < 0.001 < 0.001 0.001 - 19.4% 21.9%
IPI, International Prognostic Index; NCCN, National Comprehensive Cancer Network; GELTAMO, Grupo Español de 
Linfomas/Trasplante Autólogo de Médula Ósea.
Figure 3: Kaplan-Meier curves for overall survival according to (A) IPI, (B) NCCN-IPI, and (C) GELTAMO-IPI. 
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performed in each IPI. The prognostic significance of 
Ann Arbor staging (I/II vs. III/IV) has been reproduced 
in several studies using large cohorts [8, 9, 13]. However, 
several lines of evidence suggest that the prognostic 
role of Ann Arbor staging is at least more limited than 
other IPI factors in the rituximab era. Ziepert et al. 
performed a meta-analysis of three large clinical trials 
[5] and reported that for patients who received rituximab-
containing immunochemotherapy, Ann Arbor staging 
was not prognostic of OS in the MInT trial (p = 0.5217), 
MegaCHOEP study (p = 0.107), and RICOVER-60 
trial (p = 0.061). Moreover, application of positron 
emission tomography/computed tomography (PET/
CT) in response evaluation may affect the mitigation 
of prognostic significance of Ann Arbor staging. In 
the Danish-Canadian study conducted by El-Galaly et 
al., patients were staged and restaged by PET/CT. The 
authors reported no significant difference of prognosis 
among patients with stage I, II, and III, with only stage 
IV patients displaying an inferior OS. The 3-year OS were 
89% [95% confidence interval (CI), 83-95%], 76% (95% 
CI, 62-90%), 82% (95% CI, 70-94%), and 62% (95% CI, 
54-70%) for stage I, II, III, and IV disease, respectively 
[10]. The authors stated that the increased sensitivity of 
PET/CT may have upstaged a part of patients, particularly 
by detecting extranodal sites that would not be found by 
conventional CT [10]. Our study also integrated PET/
CT for response evaluation. It is noteworthy that as the 
modality of response evaluation shift from CT to PET/
CT, stage migration may occur, which may attenuate the 
prognostic significance of Ann Arbor staging.
Recently published studies reproduced the overall 
satisfactory prognostic stratification of DLBCL patients 
according to the NCCN-IPI in 100 to 443 DLBCL 
patients [10, 15–19]. However, in the aforementioned 
Danish-Canadian study, the NCCN-IPI was suboptimal 
to identify the high-risk group, showing that 3-year 
OS of patients with high-risk group was 48% [10]. 
Therefore, some modification of the NCCN-IPI, such 
as integrating other clinical or laboratory factors into 
the index, was tried to further improve the separation of 
patients expecting dismal outcomes. The GELTAMO-IPI 
was developed after a validation study of the NCCN-IPI 
using 2,156 patients with DLBCL from the archives of 
20 hospitals in the GELTAMO network in Spain [9]. In 
the development of GELTAMO-IPI, enhanced scorings 
were used in age and PS and involvement of extranodal 
sites were excluded. Notably, serum B2MG was 
included as an IPI factor. B2MG is a component of the 
major histocompatibility complex class I molecule, and 
it is present on all nucleated cells [20]. Elevated serum 
B2MG has been used as a prognostic indicator in the 
International Staging System of multiple myeloma [21] 
and the Follicular Lymphoma International Prognostic 
Index-2 of follicular lymphoma [22], and its potential role 
as a prognostic biomarker was reported in many subtypes 
of mature lymphoid malignancies [23–26] and lymphoma-
associated hemophagocytic lymphohistiocytosis [27]. The 
mechanism of the relationship of elevated serum B2MG to 
poor prognosis has been suggested, with B2MG proposed 
to be an indicator of heavy tumor burden with high 
cellular turnover rate [28]. However, this remains unclear 
considering that the elevation of B2MG was independent 
to serum LDH or Ann Arbor staging in previous studies [9, 
29] as well as the present study. Further investigations are 
required for this issue.
In the present study, we did not integrate any 
biologic prognostic markers recently defined or suggested 
by the advance of genomics, molecular biology, or 
immunology in the field of DLBCL. Cell of origin 
[30], stromal gene signature or its protein expression 
[31–33], double hit [34], or co-expression of MYC and 
BCL2/BCL6 (double expresser) [35] were not analyzed. 
However, the present aim is to validate and compare 
IPIs, and the above integrations are beyond the scope 
of the study. It is limitation of our study that we could 
not compare the efficiency of selecting high-risk group 
between NCCN- and GELTAMO-IPI.
Table 6: Results of reclassification calibration statistics
Comparison χ2 statistics p-value
IPI vs. NCCN-IPI IPI 6.46 0.0110
NCCN-IPI 1.69 0.1941
IPI vs. GELTAMO-IPI IPI 10.32 0.0013
GELTAMO-IPI 3.25 0.0712
NCCN-IPI vs. GELTAMO-
IPI NCCN-IPI 0.06 -
*
GELTAMO-IPI 1.60 -*
*It was impossible to calculate p-value because two cells have more than 20 subjects in the reclassification table.
IPI, International Prognostic Index; NCCN, National Comprehensive Cancer Network; GELTAMO, Grupo Español de 
Linfomas/Trasplante Autólogo de Médula Ósea.
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In conclusion, our study shows that NCCN- 
and GELTAMO-IPI have a significant advantage in 
predicting patients with poor prognosis, with 5-year OS 
rate of approximately 20 to 30%, by using basic clinical 
information and blood tests that are inexpensive and have 
a rapid turnaround time. Therefore, when selecting high-
risk patients, it would be more reasonable to use NCCN- 
or GELTAMO-IPI rather than the IPI in clinical practice.
MATERIALS AND METHODS
Patients
Analyses were conducted with patients enrolled 
in the PROCESS (Prospective Cohort Study with Risk-
Adapted Central Nervous System Evaluation in DLBCL) 
study from 27 hospitals belonging to the Consortium 
for Improving Survival of Lymphoma (CISL) in Korea. 
The original purpose, inclusion and exclusion criteria, 
and detailed information on the study conduct were as 
previously described [36]. Briefly, to evaluate risk factors 
of CNS relapse in patients with DLBCL, adult patients 
with newly diagnosed DLBCL planning to receive three 
weekly R-CHOP as a primary treatment were included. 
Patients with primary CNS DLBCL were excluded. 
Baseline evaluation of CNS involvement of DLBCL was 
recommended in any symptomatic patients or with features 
indicating a high risk for CNS involvement. However, the 
evaluation was not obligatory and there were no other 
specific interventions for the treatment of DLBCL. An 
interim and final response evaluation was conducted using 
PET/CT. The study started on August 2010 and completed 
patient enrollment on August 2012. Follow-up data 
regarding disease status and survival was updated every 
6 months, with the latest update performed in February 
2017. This study was approved by the institutional review 
boards of the participating institutions.
IPI, NCCN-IPI, and GELTAMO IPI
Risk groups were classified according to the 
scores calculated as described in the IPI, NCCN-IPI, and 
GELTAMO IPI, respectively. For the analysis with serum 
LDH and B2MG levels, normalized values (ratio to the 
ULN of each participated institution) were calculated and 
used.
Statistical analysis
PFS was time from the date of diagnosis to the date 
of disease progression, relapse, or last follow-up, or death 
from any cause. OS was defined time from diagnosis 
to death from any cause. Patient survival was analyzed 
using the Kaplan-Meier method and compared by log-
rank test. Multivariate analyses by backward conditional 
Cox regression model were conducted with variables that 
had p < 0.1 in univariate analysis. Values were two-sided 
and the significance of statistics was accepted at the level 
of p < 0.05. To compare the ability to predict high-risk 
patients between two IPIs, the risk category of each IPI 
was modified into either a high-risk or a non-high-risk 
group (patients with low-risk + LI risk + HI risk] defined 
by respective IPI. A reclassification calibration statistic 
was used, in which an IPI with smaller statistic (χ2) and 
larger p-value are considered to have better risk prediction 
than its counterpart [37].
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